| US 7,465,706 B2 | ||
| GDF3 propeptides and related methods | ||
| John Knopf, Carlisle, Mass. (US); and Jasbir Seehra, Lexington, Mass. (US) | ||
| Assigned to Acceleron Pharma Inc., Cambridge, Mass. (US) | ||
| Filed on Jun. 24, 2005, as Appl. No. 11/165,963. | ||
| Claims priority of provisional application 60/583073, filed on Jun. 24, 2004. | ||
| Prior Publication US 2006/0030520 A1, Feb. 09, 2006 | ||
| Int. Cl. A61K 38/00 (2006.01); A61K 38/16 (2006.01); C07K 14/00 (2006.01); C12N 15/00 (2006.01) | ||
| U.S. Cl. 514—12 [514/2; 530/350; 435/69.1; 435/69.7; 424/198.1] | 15 Claims |
| 1. A pharmaceutical preparation, comprising:
a) a polypeptide comprising a GDF3 propeptide having an amino acid sequence at least 95% identical to amino acids 1-219 of
SEQ ID NO: 1 and containing no more than 20 amino acids of the mature portion of human GDF3, wherein the GDF3 propeptide is
a truncated version of full-length human GDF3; and
b) a pharmaceutically acceptable carrier;
wherein the pharmaceutical preparation does not contain mature GDF3 protein, and wherein said polypeptide binds to mature
GDF3 with a Kd of at least 10−5 M and inhibits an activity of mature GDF3.
|